Business Wire

AZ-SUPIMA/TEXTILEGENESIS

13.6.2022 10:02:09 CEST | Business Wire | Press release

Share
Supima Partners With TextileGenesis to Set New Industry Benchmark on Traceability

Supima, the brand for American-grown Pima cotton, announces a strategic partnership with TextileGenesis™ to establish the new industry benchmark platform for authenticating cotton.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005099/en/

The Supima blockchain platform powered by TextileGenesis™ will digitally connect Supima’s comprehensive supply chain from the growers to the brand/retailers. Integrated with this digital platform, Supima’s technology partner Oritain™ will provide the forensic origin authentication for Supima cotton across the platform. The ability to independently validate the Supima content of products at every stage of the supply chain achieves unmatched authenticity and responsibility through the combination of forensic physical and digital authentication.

Since it was founded in 1954, SUPIMA® has been referred to as the “world’s finest cottons.” Today marks the next chapter in Supima’s ongoing leadership role in bringing the most trusted and robust verification solution to authentic premium fiber sourcing to the global fashion industry. SUPIMA® is fortunate to partner with brands and retailers that are leaders in transparency and responsible sourcing. This ground-breaking supply chain traceability platform will provide an underlying mechanism to collaborate with the partners in a transparent, and verifiable way.

TextileGenesis’ Fibercoin™ technology will be integrated into Supima’s licensing program and applied to all SUPIMA® branded fiber throughout the supply chain, creating a non-fungible digital token for every kilogram of Supima cotton that can be physically and forensically verified and authenticated by Supima from the farm through to the retail shelf. This pioneering effort for cotton sourcing sets a new standard for responsibility in the global textile industry and consumer marketplace. Supima is striving to bring deeper levels of authenticity and responsibility to cotton sourcing with greater support for equity and ubiquity for all partners in the supply chain.

“The Supima partnership with TextileGenesis provides for the very first time, undisputable proof of origin for consumer products all the way back to the fiber’s origin. This enables Supima’s partner brands to credibly claim advantages in terms of product quality and sustainability that are independently verifiable through both digital and forensic testing. There is no system like this for any other fiber. SUPIMA® partners will have the most authentic and trustworthy premium cotton source for all the current and future needs of luxury apparel and home textile products,” says Marc Lewkowitz, President and CEO of Supima.

“This collaboration is setting a new benchmark for the cotton and premium fiber’s industry, and paves a new path for the entire fashion eco-system. We are creatively combining three major innovations - digital-tokens based article-level traceability, forensic physical verification, and Supima brand-licensing - in a single integrated platform. It creates a new platinum standard in the industry for end-to-end traceability and physical verification,” says Amit Gautam, Founder and CEO of TextileGenesis.

ABOUT TEXTILEGENESIS
TextileGenesis is a market-leading traceability platform custom-built for the fashion and textile ecosystem. It has partnered with 40+ leading global brands to create fiber-to-retail traceability for sustainable, premium and certified materials. By the end of 2022, TextileGenesis will create traceability for 500 million+ units in the global fashion industry.

ABOUT SUPIMA
Supima is America’s luxury cotton: founded in 1954, the Supima brand, short for “Superior Pima,” designates an exclusive source of exceptional extra-long staple cotton responsibly grown only in the West and the Southwestern U.S. It is prized the world over by designers and discerning consumers who value its resilient strength, lasting color, indulgent softness, and durability.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye